Department of Cardiology.
International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Coron Artery Dis. 2023 Mar 1;34(2):134-137. doi: 10.1097/MCA.0000000000001215. Epub 2023 Jan 4.
Patients undergoing transcatheter aortic valve implantation (TAVI) due to severe aortic stenosis have a high prevalence of coronary artery disease (CAD). As many of them have high surgical risk, CAD treatment in this group has typically been carried out with optimal medical treatment or paired with percutaneous coronary intervention (PCI). However, the best approach in this scenario is not well established. We aimed to evaluate 5-year cardiovascular outcomes in patients with aortic stenosis and chronic CAD treated with medical treatment alone compared to PCI coupled with medical therapy before or during TAVI. We used data from a large multinational electronic health record network (TriNetX). Patients aged 18 years or older with severe aortic stenosis and CAD who underwent TAVI in the last 10 years before the analysis were considered eligible. Five-year Kaplan-Meier curves and hazard ratios were calculated. We identified 19 058 patients undergoing isolated TAVI and 2277 patients undergoing TAVI and PCI. Using propensity matching scores, 2277 patients in each group were compared. The 5-year cumulative incidence of MACE was 22.92% in the isolated TAVI group, vs. 25.91% in the PCI-TAVI group. The probability of the composite primary outcome was not significantly different between the isolated TAVI group vs. the PCI-TAVI group [53.1 vs. 47.6%, adjusted hazard ratio (HR) 0.92, 95% confidence interval (CI), 0.80-1.05]. In a real-world study of patients with CAD and severe aortic stenosis, the 5-year probability of death, acute coronary syndrome and ischemic stroke did not differ between patients undergoing isolated TAVI compared to patients undergoing PCI before or during TAVI.
患有严重主动脉瓣狭窄的经导管主动脉瓣植入术(TAVI)患者中,冠状动脉疾病(CAD)的患病率很高。由于其中许多患者的手术风险较高,因此该组患者的 CAD 治疗通常采用最佳药物治疗或与经皮冠状动脉介入治疗(PCI)联合治疗。然而,这种情况下的最佳方法尚未得到很好的确立。我们旨在评估单独接受药物治疗与 PCI 联合药物治疗(在 TAVI 之前或期间)治疗的主动脉瓣狭窄合并慢性 CAD 患者的 5 年心血管结局。我们使用了来自大型跨国电子健康记录网络(TriNetX)的数据。在分析前的过去 10 年中,患有严重主动脉瓣狭窄和 CAD 的年龄在 18 岁或以上并接受 TAVI 的患者被认为符合条件。计算了 5 年的 Kaplan-Meier 曲线和风险比。我们确定了 19058 例接受单独 TAVI 的患者和 2277 例接受 TAVI 和 PCI 的患者。使用倾向评分匹配,比较了每组中的 2277 例患者。单独 TAVI 组的 5 年累积 MACCE 发生率为 22.92%,而 PCI-TAVI 组为 25.91%。复合主要结局的概率在单独 TAVI 组与 PCI-TAVI 组之间没有显著差异[53.1%比 47.6%,调整后的危险比(HR)0.92,95%置信区间(CI)0.80-1.05]。在一项患有 CAD 和严重主动脉瓣狭窄的患者的真实世界研究中,与单独接受 TAVI 的患者相比,在 TAVI 之前或期间接受 PCI 的患者的 5 年死亡、急性冠状动脉综合征和缺血性卒中的概率没有差异。